Epigenetics Control Cell Differentiation and Gene Expression

What if…

Epigenetics worked through a universal system and we could interrogate that system and therapeutically intervene to control gene expression?

It turns out…

Nature has organized genes and their regulatory elements in conserved 3D structures called Insulated Genomic Domains (IGDs). This is nature’s universal operating system for genomic control, which Omega has therapeutically harnessed, through epigenomic programming™, to create a new class of therapeutics, epigenomic controllers™.

Our breakthrough science has enabled us to tap into this universal operating system for genomic control to systematically address and target the most fundamental genomic processes which fuel cellular growth, differentiation and gene expression.

This is the promise of
Omega’s Epigenomic Programming™ platform

UNDERSTANDING NATURE’S UNIVERSAL OPERATING SYSTEM

Nature has organized genes and their regulatory elements in conserved 3D structures called Insulated Genomic Domains (IGDs) to control gene expression. IGDs encompass single or multiple genes and their regulatory elements. They are insulated from outside transcription by CTCF binding. At Omega, we understand the topology and the functionality of these IGDs through both computational and biological insights. We have leveraged Artificial Intelligence to categorize the roughly 15,000 human IGDs and their elements into genomic “zip codes” that we target with high specificity. We understand how they differ between pristine and diseased states, and these insights inform the Company’s approach to IGDs as drug targets to treat and potentially cure disease.

The Insulated Genomic Domain (IGD) as a drug target

A New and Unprecedented Class of Medicine, Omega Epigenomic Controllers™

Omega has created a new category of medicine through its epigenomic programming platform. We are developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers, that specifically and durably modulate and tune the level of expression of any of the 25,000+ human genes, individually or collectively, to treat and cure disease. Omega’s medicines are being developed to be dosed only as frequently as therapeutically necessary by intervening at the pre-transcriptional level without making changes to native nucleic acid sequences.

This is Precision Genomic Control™

Our vision is to fundamentally transform the
practice of human medicine to treat and cure disease.

THE OMEGA THERAPEUTICS STORY

About Omega
Therapeutics

Nature’s Universal
Operating System

Our Transformative
Platform Technology

In The News

Top Life Sciences Startups to Watch in 2021

Omega Therapeutics named to BioSpace’s Next Gen Bio “Class of 2021”, a list of up-and-coming life sciences companies in North America that recently launched and are expected to make an enormous impact on the industry now and continue into the future.

Read More
Inside Omega Therapeutics' Epigenomic Controllers™

Omega Therapeutics is developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers, that are designed to target with high specificity and downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease.

Read More
Flagship-backed startup raises $85M for 'gene-tuning' drugs

One of Flagship Pioneering’s latest startups has raised $85 million to develop drugs using a scientific approach that is seeing renewed attention.

Read More
'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech

Omega Therapeutics began, as all biotech fledglings incubated at Flagship Labs do, with an off-the-wall question: Can one control gene expression but not create the massive nucleic acid sequence changes that are created by gene therapy and gene editing?

Read More
Managing a pharma company during three crises: lessons learned for Covid-19

When I started working in the biopharma industry 20 or so years ago, I didn’t think I would need to become an expert in crisis management.

Read More